Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis

Bone Marrow Transplantation volume 47, pages 810–816 (2012)Cite this article

Abstract

Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in advanced phases of CML, which may permit early allografting for responding patients. To identify prognostic factors in allograft recipients previously treated with IM, we analyzed 449 allogeneic hematopoietic SCTs performed from 1999 to 2004 in advanced-phase CML, using the data reported to the Center for International Blood and Marrow Transplant Research. CML patients in second chronic phase (CP2, n=184), AP (n=185) and BP (n=80) received HLA-identical sibling (27%), related (3%), or matched or mismatched unrelated donor (70%), peripheral blood (47%) or BM (53%) hematopoietic SCT after myeloablative (78%) or non-myeloablative (22%) conditioning. In all, 52% in CP2, 49% in AP and 46% in BP received IM before hematopoietic SCT. Disease-free survival was 35–40% for CP2, 26–27% for AP and 8–11% for BP. Cumulative incidence of acute and chronic GVHD and TRM were not affected by the stages of CML or pre-hematopoietic SCT IM exposure. Multivariate analyses showed that conventional prognostic indicators remain the strongest determinants of transplant outcomes. In conclusion, there are no new prognostic indicators of the outcomes of allogeneic hematopoietic SCT for advanced-phase CML in the IM era.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937.

    Article  CAS  Google Scholar 

  2. Kantarjian HM, O’Brien S, Cortes JE, Smith TL, Rios MB, Shan J et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002; 8: 2167–2176.

    CAS  PubMed  Google Scholar 

  3. Sureda A, Carrasco M, de Miguel M, Martinez JA, Conde E, Sanz MA et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 2003; 88: 1213–1220.

    CAS  PubMed  Google Scholar 

  4. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539.

    Article  CAS  Google Scholar 

  5. Kantarjian HM, Cortes J, O’Brien S, Giles FJ, Albitar M, Rios MB et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99: 3547–3553.

    Article  CAS  Google Scholar 

  6. Oehler VG, Gooley T, Snyder DS, Johnston L, Lin A, Cummings CC et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109: 1782–1789.

    Article  CAS  Google Scholar 

  7. Perz JB, Khorashad JS, Marin D, Apperley JF, Olavarria E . Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia. Haematologica 2006; 91: 1145–1146.

    PubMed  Google Scholar 

  8. Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006; 91: 452–459.

    CAS  PubMed  Google Scholar 

  9. Bornhauser M, Kroger N, Schwerdtfeger R, Schafer-Eckart K, Sayer HG, Scheid C et al. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Eur J Haematol 2006; 76: 9–17.

    Article  Google Scholar 

  10. Zaucha JM, Prejzner W, Giebel S, Gooley TA, Szatkowski D, Kalwak K et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 417–424.

    Article  CAS  Google Scholar 

  11. Shimoni A, Kroger N, Zander AR, Rowe JM, Hardan I, Avigdor A et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003; 17: 290–297.

    Article  CAS  Google Scholar 

  12. Tiribelli M, Marin L, Calistri E, Geromin A, Damiani D, Fanin R . Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias. Bone Marrow Transplant 2004; 34: 827–828.

    Article  CAS  Google Scholar 

  13. Wassmann B, Pfeifer H, Scheuring U, Klein SA, Gokbuget N, Binckebanck A et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia 2002; 16: 2358–2365.

    Article  CAS  Google Scholar 

  14. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115: 1880–1885.

    Article  CAS  Google Scholar 

  15. Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008; 14: 748–758.

    Article  Google Scholar 

  16. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.

    Article  CAS  Google Scholar 

  17. Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008; 112: 3500–3507.

    Article  CAS  Google Scholar 

  18. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087–1092.

    Article  CAS  Google Scholar 

  19. Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA . Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004; 125: 613–620.

    Article  Google Scholar 

  20. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969–2976.

    Article  CAS  Google Scholar 

  21. Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542–2551.

    Article  Google Scholar 

  22. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–2541.

    Article  CAS  Google Scholar 

  23. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009; 27: 6041–6051.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The CIBMTR is supported by the Public Health Service Grant/cooperative agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a grant/cooperative agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two grants, N00014-06-1-0704 and N00014-08-1-0058, from the Office of Naval Research; and grants from AABB; Allos, Inc.; Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US, Inc.; Be the Match Foundation; Biogen IDEC; BioMarin Pharmaceutical, Inc.; Biovitrum AB; BloodCenter of Wisconsin; Blue Cross and Blue Shield Association; Bone Marrow Foundation; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research Association; ClinImmune Labs; CTI Clinical Trial and Consulting Services; Eisai, Inc.; Genentech, Inc.; Genzyme Corporation; Histogenetics, Inc.; HKS Medical Information Systems; Hospira, Inc.; Kirin Brewery Co., Ltd.; The Leukemia & Lymphoma Society; Merck & Company; The Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Miller Pharmacal Group; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Nature Publishing Group; Novartis Oncology; Oncology Nursing Society; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Pall Life Sciences; Pfizer Inc; Schering Corporation; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, Inc.; StemSoft Software, Inc.; Sysmex America, Inc.; THERAKOS, Inc.; Vidacare Corporation; ViraCor Laboratories; ViroPharma, Inc. and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense or any other agency of the US Government. We are grateful to Drs Manuel M Abecasis, Joseph Antin, Brian J Bolwell, Matthew Carabasi, Francisco Cervantes, Richard A Champlin, Edward Copelan, Gregory A Hale, Jane Liesveld, Mark R Litzow; Eduardo Olivaria and Harry C Schouten for their thoughtful comments and suggestions.

Author information

Authors and Affiliations

  1. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA

    H J Khoury

  2. Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA

    M Kukreja, T Wang & M M Horowitz

  3. Imperial College-Hammersmith Hospital, London, UK

    J M Goldman

  4. University Hospital Basel, Basel, Switzerland

    J Halter

  5. University of Minnesota Medical Center, Minneapolis, MN, USA

    M Arora

  6. Princess Margaret Hospital, Toronto, Ontario, Canada

    V Gupta & A Keating

  7. Duke University Medical Center, Durham, NC, USA

    D A Rizzieri

  8. Christian Medical College Hospital, Vellore, India

    B George

  9. Celgene Corporation, Summit, NJ, USA

    R P Gale

  10. Bristol Adult BMT Unit, Bristol

    D I Marks

  11. , UK,

    D I Marks

  12. Roswell Park Cancer Institute, Buffalo, NY, USA

    P L McCarthy

  13. Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    A Woolfrey & S J Lee

  14. Royal Melbourne Hospital City Campus, Melbourne, Australia

    J Szer

  15. MD Anderson Cancer Center, Houston, TX, USA

    S A Giralt & J Cortes

  16. Oregon Health and Science University, Portland, OR, USA

    R T Maziarz

Authors
  1. H J Khoury
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Kukreja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J M Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Halter
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Arora
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D A Rizzieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B George
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. R P Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. D I Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. P L McCarthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A Woolfrey
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. J Szer
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S A Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. R T Maziarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. J Cortes
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. M M Horowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. S J Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H J Khoury.

Ethics declarations

Competing interests

Drs J Cortes and DA Rizzieri have received research funding from the Novartis. Dr Rizzieri also received an honorarium from Novartis. Dr Jeffrey Szer received a consultant or advisory role compensation from Novartis.

Additional information

This work was presented as a poster at the Annual Meeting of the CIBMTR in February 2009.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khoury, H., Kukreja, M., Goldman, J. et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant 47, 810–816 (2012). https://doi.org/10.1038/bmt.2011.194

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.194

Keywords

This article is cited by

Search

Advanced search

Quick links